These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 36794863)

  • 21. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
    Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
    Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment Patterns and Costs in Biologic DMARD-Naive Patients with Rheumatoid Arthritis Initiating Etanercept or Adalimumab with or Without Methotrexate.
    Tkacz J; Gharaibeh M; DeYoung KH; Wilson K; Collier D; Oko-Osi H
    J Manag Care Spec Pharm; 2020 Mar; 26(3):285-294. PubMed ID: 32105179
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database.
    Sruamsiri R; Iwasaki K; Tang W; Mahlich J
    BMC Dermatol; 2018 Jul; 18(1):5. PubMed ID: 29996929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The journey for US psoriasis patients prescribed a topical: a retrospective database evaluation of patient progression to oral and/or biologic treatment.
    Wu JJ; Lu M; Veverka KA; Smulders M; Papademetriou E; Yu J; Feldman SR
    J Dermatolog Treat; 2019 Aug; 30(5):446-453. PubMed ID: 30554541
    [No Abstract]   [Full Text] [Related]  

  • 25. Treatment Patterns for Targeted Therapies, Non-Targeted Therapies, and Drug Holidays in Patients with Psoriasis.
    Armstrong A; Xia Q; John AR; Patel V; Seigel L
    Dermatol Ther (Heidelb); 2022 Sep; 12(9):2087-2103. PubMed ID: 35947341
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug Survival of Biological Therapies for Psoriasis Treatment in Germany and Associated Costs: A Retrospective Claims Database Analysis.
    Mahlich J; Alba A; Hadad LE; Leisten MK; Peitsch WK
    Adv Ther; 2019 Jul; 36(7):1684-1699. PubMed ID: 31102203
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment patterns and costs for anti-TNFα biologic therapy in patients with psoriatic arthritis.
    Palmer JB; Li Y; Herrera V; Liao M; Tran M; Ozturk ZE
    BMC Musculoskelet Disord; 2016 Jun; 17():261. PubMed ID: 27301458
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study.
    Corral M; DeYoung K; Kong AM
    BMC Pulm Med; 2020 Jul; 20(1):188. PubMed ID: 32652979
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dose escalation and associated costs in biologic treatment of psoriasis based on real-world data.
    Bagel J; Glick B; Wu JJ; Chopra I; Song X; Brouillette M; Mendelsohn A; Rozzo S; Han G
    J Med Econ; 2021; 24(1):782-791. PubMed ID: 34107834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Psoriasis treatment patterns: a retrospective claims study.
    Higa S; Devine B; Patel V; Baradaran S; Wang D; Bansal A
    Curr Med Res Opin; 2019 Oct; 35(10):1727-1733. PubMed ID: 31081697
    [No Abstract]   [Full Text] [Related]  

  • 31. Treatment patterns and healthcare costs among patients with psoriasis initiating apremilast or biologics: a retrospective claims database cohort analysis.
    Wu JJ; Wang CA; Jobson G; Davidson D; Kalirai S; Zhu J; Suryavanshi M; Mittal M; Patel V; Seigel L
    J Dermatolog Treat; 2023 Dec; 34(1):2177095. PubMed ID: 36736349
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment Patterns Among Patients with Psoriatic Arthritis Treated with a Biologic in the United States: Descriptive Analyses from an Administrative Claims Database.
    Walsh JA; Adejoro O; Chastek B; Palmer JB; Hur P
    J Manag Care Spec Pharm; 2018 Jul; 24(7):623-631. PubMed ID: 29952704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retrospective Database Analysis: Dose Escalation and Adherence in Patients Initiating Biologics for Ulcerative Colitis.
    Long MD; Cohen RD; Smith TW; DiBonaventura M; Gruben D; Bargo D; Salese L; Quirk D
    Dig Dis; 2022; 40(5):553-564. PubMed ID: 34879378
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
    Iskandar IYK; Ashcroft DM; Warren RB; Evans I; McElhone K; Owen CM; Burden AD; Smith CH; Reynolds NJ; Griffiths CEM
    Br J Dermatol; 2017 May; 176(5):1297-1307. PubMed ID: 27589476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health Care Resource Utilization and Costs Associated With Switching Biologics in Rheumatoid Arthritis.
    Vanderpoel J; Tkacz J; Brady BL; Ellis L
    Clin Ther; 2019 Jun; 41(6):1080-1089.e5. PubMed ID: 31122662
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-World Claims Analyses of Comorbidity Burden, Treatment Pattern, Healthcare Resource Utilization, and Costs in Pediatric Psoriasis.
    Edson-Heredia E; Anderson S; Guo J; Zhu B; Malatestinic WN; Wine-Lee L; Swanson E
    Adv Ther; 2021 Jul; 38(7):3948-3961. PubMed ID: 34091866
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world biologic and apremilast treatment patterns and healthcare costs in moderate-to-severe plaque psoriasis.
    Feldman SR; Zhang J; Martinez DJ; Lopez-Gonzalez L; Marchlewicz EH; Shrady G; Mendelsohn AM; Zhao Y
    Dermatol Online J; 2021 Jan; 27(1):. PubMed ID: 33560784
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world treatment patterns and healthcare costs of biologics and apremilast among patients with moderate-to-severe plaque psoriasis by metabolic condition status.
    Feldman SR; Zhang J; Martinez DJ; Lopez-Gonzalez L; Marchlewicz EH; Shrady G; Mendelsohn AM; Zhao Y
    J Dermatolog Treat; 2021 Mar; 32(2):203-211. PubMed ID: 31769703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis.
    Fonia A; Jackson K; Lereun C; Grant DM; Barker JN; Smith CH
    Br J Dermatol; 2010 Oct; 163(4):807-16. PubMed ID: 20662837
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ixekizumab treatment patterns and healthcare utilization and costs for patients with psoriasis.
    Murage MJ; Gilligan AM; Tran O; Goldblum O; Burge R; Lin CY; Qureshi A
    J Dermatolog Treat; 2021 Feb; 32(1):56-63. PubMed ID: 31696745
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.